Laboratorios Farmaceuticos Rovi, S.A./ADR

Drug Name	Phase	Indication	Designations	Patent
Celecoxib + Acetaminohen	Phase 3	Joint Pain	-	-
Depigoid Parietaria judaica 1000DPP/ml	Phase 3	Allergic Rhinoconjunctivitis	-	-
Glucosamine and chondroitin sulfate combination (Eurofarma)	Phase 3	Osteoarthritis of Knee	-	-
Minoxidil Topical Foam	Phase 3	Alopecia	-	-
Study group - quadrivalent recombinant hemagglutinin influenza vaccine	Phase 3	Influenza, Human	-	-
Rizatriptan 10 mg + Naproxen 550mg	Phase 3	Migraine	-	-
Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg	Phase 3	Asthma Copd	-	-
Nimotuzumab	Phase 3	Esophageal Cancer	-	-
Fixed combination of budesonide and formoterol	Phase 3	Asthma	-	-
Filgrastim (Eurofarma)	Phase 3	Neutropenia in Breast Cancer	-	-
DMMET-01	Phase 3	Diabetes Type 2	-	-
Chlorthalidone 25 mg + amiloride hydrochloride 5 mg	Phase 3	Arterial Hypertension	-	-
Dexketoprofen/Vitamin B	Phase 3	Acute Low Back Pain	-	-
Lactase	Phase 3	Hypolactasia	-	-
Foraseq	Phase 3	ASTHMA	-	-
FDC of codeine 30 mg/dipyrone 500 mg	Phase 3	Pain	-	-
Immunotherapy with modified extract of O. europaea pollen	Phase 3	Allergy	-	-
Etoricoxib + Cyanocobalamin fixed dose	Phase 3	Acute Low-back Pain	-	-
Desloratadine / Betamethasone in fixed dose	Phase 3	Allergic Rhinitis	-	-
Mometasone furoate	Phase 3	Mild to Moderate Persistent Allergic Rhinitis	-	-
FDC of oxycodone 5 mg/ibuprofen 400 mg	Phase 3	Pain	-	-
Noex	Phase 3	Allergic Rhinitis	-	-
Metformin hydrochloride	Phase 3	Type 2 Diabetes	-	-
Desloratadine , Prednisolone	Phase 3	Allergic Rhinitis	-	-
Fixed Dose Etoricoxib + Betamethasone	Phase 3	Bursitis	-	-
Etoricoxib 90 mg + diacerein 50 mg	Phase 3	Pain Management	-	-
Treatment with nifedipine	Phase 3	High Blood Pressure (& [Essential Hypertension])	-	-
Losartan/Chlorthalidone in fixed dose	Phase 3	Essential Arterial Hypertension	-	-
Etoricoxib + Tizanidine fixed dose	Phase 3	Acute Low-back Pain	-	-
Levetiracetam	Phase 3	Epilepsy	-	-
Candicort®	Phase 3	Tinea	-	-
Glucosamine sulphate and chondroitin sulphate association	Phase 3	Osteoarthritis of the Knee	-	-
Group 1	Phase 3	Nasal Congestion and Inflammations	-	-
A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)	Phase 3	Type 2 Diabetes	-	-
Etoricoxib 90 mg / Tramadol 50 mg	Phase 3	Acute Low Back Pain	-	-
Sodium picosulphate, light magnesium oxide and anhydride citric acid.	Phase 3	Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.	-	-
Celecoxib+Pregabalin+Vitamin B fixed dose	Phase 3	Chronic Low-back Pain	-	-
Immunotherapy with modified extract of Olea europaea pollen	Phase 3	Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen	-	-
glucosamine sulfate /chondroitin sulfate - capsules	Phase 3	Knee Osteoarthritis	-	-
Difluprednate 0.05%	Phase 3	Cataract	-	-
Lactase Oral Tablets	Phase 3	Lactose Intolerance	-	-
Lucentis®	Phase 3	Diabetic Macular Edema	-	-
Liquaemin	Phase 3	Hemodialysis Complication	-	-
Alleance®	Phase 3	Myopia	-	-
application of the topic gel	Phase 3	Acne Vulgaris	-	-
Salmeterol/Fluticasone	Phase 3	Asthma	-	-
Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.	Phase 3	Hypercholesterolemia	-	-
Dextralgen	Phase 3	Lumbar Sciatic Pain	-	-
Etoricoxib + Betamethasone fixed dose	Phase 3	Gout Arthritis	-	-
Inj. Goserelin (Test) Subcutaneously	Phase 3	Advanced Prostate Cancer	-	-
brompheniramine + phenylephrine	Phase 3	Nasal Congestion and Inflammations	-	-
Eszopiclone	Phase 3	INSOMNIA	-	-
Ibuprofen + Loratadine fixed dose	Phase 3	Common Cold	-	-
Formoterol/Budesonide	Phase 3	Asthma	-	-
Meloxicam	Phase 3	Dysmenorrhea	-	-
Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)	Phase 3	Cold	-	-
Pregabalin 75mg/ Tramadol 50 mg	Phase 3	Neuropathic Pain	-	-
Formoterol/Fluticasone	Phase 3	Asthma	-	-
Moxifloxacin / Dexamethasone Ophthalmic Solution	Phase 3	Cataract Extraction	-	-
Metformin Glycinate	Phase 3	Severe Acute Respiratory Syndrome Coronavirus 2	-	-
Allergen extract (Phleum pratense)	Phase 3	Seasonal Allergic Rhinitis	-	-
Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Dactylis Glomerata)	-	-
DP/MG/14-1	Phase 2	Rhinitis	-	-
AS012	Phase 2	Non-segmental Vitiligo	-	-
1 (Dose Response Skin Prick Tests)	Phase 2	Cat Allergy (Disorder)	-	-
Prick test Chenopodium album allergen extract	Phase 2	Allergy to Chenopodium Album	-	-
Immunotherapy with modified extract of P. pratense pollen	Phase 2	Rhinitis, Allergic, Seasonal	-	-
Grass pollen allergenic extract (L. perenne-C. dactylon )	Phase 2	Allergic Rhinoconjunctivitis	-	-
Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)	Phase 2	Allergy	-	-
Cupressus arizonica	Phase 2	Allergy to Tree Pollen	-	-
Prick test Platanus acerifolia allergen extract	Phase 2	Allergy to Platanus Acerifolia	-	-
Four different concentrations of Secale cereale allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Secale Cereale)	-	-
COVID-19 vaccine HIPRA 10	Phase 2	Covid19	-	-
Evogliptin	Phase 2	Diabetes Mellitus, Type 2	-	-
Four different concentrations of Poa pratensis allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen	-	-
Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control	Phase 2	Allergy to Mites	-	-
Sodium Hyaluronate Ophthalmic 0.4% BID	Phase 2	Dry Eye	-	-
four differente concentrations of Alternaria alternata allergen extract, positive control and negative control	Phase 2	Allergy to Alternaria Fungus	-	-
Artemisia vulgaris	Phase 2	Allergy to Pollen	-	-
etoricoxib-tramadol	Phase 2	Acute Pain	-	-
PRO-157	Phase 2	Bacterial Conjunctivitis	-	-
Lolium allergen extract	Phase 2	Allergy to Grass Pollen	-	-
Prick test Dermatophagoides pteronyssinus allergen extract	Phase 2	Allergy Dermatophagoides Pteronyssinus	-	-

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Laboratorios Farmaceuticos Rovi, S.A./ADR

Market Overview

LRVIY News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals